Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by Cornell Pochily Investment Advisors Inc.

Cornell Pochily Investment Advisors Inc. increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.0% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 6,335 shares of the medical research company’s stock after purchasing an additional 124 shares during the quarter. Thermo Fisher Scientific makes up approximately 1.4% of Cornell Pochily Investment Advisors Inc.’s investment portfolio, making the stock its 17th largest position. Cornell Pochily Investment Advisors Inc.’s holdings in Thermo Fisher Scientific were worth $3,363,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in TMO. Moneta Group Investment Advisors LLC grew its holdings in shares of Thermo Fisher Scientific by 104,536.8% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 8,355,245 shares of the medical research company’s stock worth $4,601,150,000 after purchasing an additional 8,347,260 shares during the period. Providence Capital Advisors LLC lifted its stake in Thermo Fisher Scientific by 61,754.7% during the 1st quarter. Providence Capital Advisors LLC now owns 5,842,175 shares of the medical research company’s stock worth $10,136,000 after acquiring an additional 5,832,730 shares in the last quarter. Norges Bank purchased a new stake in Thermo Fisher Scientific during the fourth quarter worth approximately $3,105,677,000. Morgan Stanley increased its holdings in shares of Thermo Fisher Scientific by 17.7% in the fourth quarter. Morgan Stanley now owns 11,730,063 shares of the medical research company’s stock valued at $6,459,629,000 after purchasing an additional 1,764,312 shares during the period. Finally, Loomis Sayles & Co. L P increased its holdings in shares of Thermo Fisher Scientific by 17,046.7% in the third quarter. Loomis Sayles & Co. L P now owns 973,591 shares of the medical research company’s stock valued at $492,803,000 after purchasing an additional 967,913 shares during the period. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Trading Down 0.1 %

NYSE:TMO traded down $0.35 during trading hours on Thursday, hitting $579.02. 157,742 shares of the stock were exchanged, compared to its average volume of 1,603,173. The company’s 50 day moving average is $564.32 and its two-hundred day moving average is $519.80. The company has a market capitalization of $220.79 billion, a P/E ratio of 37.50, a price-to-earnings-growth ratio of 2.39 and a beta of 0.80. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $603.82. The company has a quick ratio of 1.39, a current ratio of 1.75 and a debt-to-equity ratio of 0.67.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The firm had revenue of $10.89 billion during the quarter, compared to analysts’ expectations of $10.73 billion. During the same quarter in the prior year, the company earned $5.40 EPS. The company’s revenue was down 4.9% on a year-over-year basis. On average, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, April 15th. Shareholders of record on Friday, March 15th will be issued a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.27%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date is Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.10%.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total value of $5,556,300.00. Following the transaction, the chief executive officer now owns 49,155 shares in the company, valued at approximately $27,311,992.65. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, Director Debora L. Spar sold 164 shares of the business’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the sale, the director now owns 1,207 shares of the company’s stock, valued at $660,192.79. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the completion of the transaction, the chief executive officer now directly owns 49,155 shares of the company’s stock, valued at $27,311,992.65. The disclosure for this sale can be found here. Insiders sold a total of 50,277 shares of company stock valued at $28,513,384 in the last three months. Company insiders own 0.32% of the company’s stock.

Analyst Ratings Changes

Several analysts have weighed in on the company. Barclays lowered Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and upped their target price for the company from $475.00 to $555.00 in a report on Wednesday, January 24th. Royal Bank of Canada upped their price objective on Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a research report on Thursday, February 1st. Citigroup initiated coverage on Thermo Fisher Scientific in a research report on Monday, March 18th. They issued a “neutral” rating and a $620.00 price objective on the stock. Wolfe Research assumed coverage on Thermo Fisher Scientific in a research report on Wednesday, December 13th. They issued an “outperform” rating and a $575.00 price objective on the stock. Finally, HSBC assumed coverage on Thermo Fisher Scientific in a research report on Monday, December 18th. They set a “buy” rating and a $610.00 target price on the stock. Five research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average target price of $599.00.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.